Kanamab is a recombinant humanized monoclonal antibody specifically targeting interleukin-1 β (IL-1 β) for targeted therapy, belonging to the IgG1/kappa subtype.

1、 Drug name and main ingredients

1. Common name: Canakinumab

2. Product Name: ILARIS ®

3. Dosage form: Subcutaneous injection freeze-dried powder injection

4. Main ingredients: Each bottle contains 180mg of kanamycin (active ingredient), and excipients include sucrose, L-histidine, and polysorbate 80.

2、 Indications

Cold Pyrroline Associated Periodic Syndrome (CAPS): Suitable for the treatment of CAPS in adults and children aged 4 years and above, including Familial Cold Autoinflammatory Syndrome (FCAS) and Mukel Wells Syndrome (MWS).

3、 Specifications and characteristics

1. Specification: 180mg/bottle (single dose 6mL glass bottle freeze-dried powder).

2. Appearance: White freeze-dried powder, after reconstitution, it is colorless to light brownish yellow clear or microemulsion light solution, with no visible particles.

4、 Usage and dosage

1. Recommended dosage: 150mg per dose for patients weighing over 40kg, 2mg/kg per dose for patients weighing 15-40kg (increased to 3mg/kg if efficacy is insufficient), subcutaneous injection once every 8 weeks.

2. Dissolve slowly in 1mL sterile injection water per bottle, gently shake at a 45 ° angle for 1 minute, let it stand for 15 minutes, and avoid shaking. Use within 60 minutes after reconstitution or refrigerate (2-8 ° C) for 4 hours.

3. Omission treatment: If it exceeds 12 hours, skip and administer according to the original plan next time; No need to take additional medication after vomiting.

5、 Dose adjustment

1. Weight adjustment: For children weighing 15-40kg, the initial dose is 2mg/kg, which can be increased to 3mg/kg;

2. Combination use of strong CYP3A inhibitors: dose reduction is required.

6、 Medication precautions

1. Infection risk: Screening for latent tuberculosis before treatment and avoiding medication during the active infection period;

2. Vaccination: Live vaccines are prohibited, and recommended vaccination should be completed before treatment;

3. Resolution operation: Strictly aseptic operation to avoid injection into scar tissue.

7、 Medication for special populations

1. Pregnant women: use only when necessary (animal experiments show delayed fetal bone development);

2. Breastfeeding period: use with caution (unknown if it is secreted through milk);

3. Children: Safe and effective for ages ≥ 4, insufficient data for ages<4.

8、 Adverse reactions

1. Common (≥ 10%): Nasopharyngitis (34%), Diarrhea (20%), Influenza (17%), Headache (14%), Nausea (14%);

2. Serious reactions: dizziness (9-14%), severe infection (3%).

9、 Contraindications

There are no absolute contraindications, but it is contraindicated for those who are allergic to the ingredients.

10、 Drug interactions

1. TNF inhibitors: Combination use increases the risk of serious infections, avoid co use;

2. CYP450 substrates: It may be necessary to adjust the dosage of narrow therapeutic index drugs such as warfarin.

11、 Storage method

Unopened bottles should be refrigerated at 2-8 ° C and kept away from light. After reconstitution, use at room temperature for 1 hour or refrigerated for 4 hours.

12、 Manufacturer

Manufacturer: Novartis Pharma Stein AG, Switzerland.

Note: If there is persistent infection, severe dizziness, or allergic reaction, seek medical attention immediately.

Ilarisinformation